ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Medpace Holdings Inc

Medpace Holdings Inc (MEDP)

443.00
8.01
(1.84%)
Closed July 14 4:00PM
443.00
-0.23
(-0.05%)
After Hours: 7:56PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
443.00
Bid
390.00
Ask
450.00
Volume
266,934
431.00 Day's Range 444.87
227.21 52 Week Range 444.87
Market Cap
Previous Close
434.99
Open
436.22
Last Trade
6
@
441.1
Last Trade Time
Financial Volume
$ 117,908,693
VWAP
441.7148
Average Volume (3m)
206,730
Shares Outstanding
30,983,399
Dividend Yield
-
PE Ratio
48.56
Earnings Per Share (EPS)
9.13
Revenue
1.89B
Net Profit
282.81M

About Medpace Holdings Inc

Medpace Holdings Inc is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in North America, Europe, Africa, Middle East, Asia-Pacific and Latin Am... Medpace Holdings Inc is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in North America, Europe, Africa, Middle East, Asia-Pacific and Latin America. Show more

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Medpace Holdings Inc is listed in the Coml Physical, Biologcl Resh sector of the NASDAQ with ticker MEDP. The last closing price for Medpace was $434.99. Over the last year, Medpace shares have traded in a share price range of $ 227.21 to $ 444.87.

Medpace currently has 30,983,399 shares outstanding. The market capitalization of Medpace is $13.48 billion. Medpace has a price to earnings ratio (PE ratio) of 48.56.

Medpace (MEDP) Options Flow Summary

Overall Flow

Bullish

Net Premium

84k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

MEDP Latest News

Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024

Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2024 financial results after the market close on Monday, July 22, 2024. The Company will...

Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News

Apple (NASDAQ:AAPL) – Smartphone shipments from Apple in China fell 19% in the first quarter due to competition from Huawei. Its market share decreased to 15.7%, nearly matching that of...

Medpace Holdings, Inc. Reports First Quarter 2024 Results

Revenue of $511.0 million in the first quarter of 2024 increased 17.7% from revenue of $434.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
139.539.79750662998403.47444.87396.5173608418.81535266CS
451.6113.1863358798391.39444.87386.425186687409.39730641CS
1267.517.9760319574375.5444.87355.79206730398.8631651CS
26155.2953.9744881999287.71444.87277.72229177384.91621277CS
52201.0583.0956809258241.95444.87227.21247245318.41549612CS
156259.14140.944196671183.86444.87126.945289871221.44825511CS
260380.9613.36553945262.1444.8758.72287957175.27390145CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VEVVicinity Motor Corporation
$ 0.7131
(122.15%)
116.26M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
IVPInspire Veterinary Partners Inc
$ 10.52
(88.19%)
41.79M
TOYOTOYO Company Ltd
$ 2.699
(74.13%)
56.65M
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
(51.33%)
7.4M
SISIShineco Inc
$ 0.8446
(-60.16%)
6.71M
MCACMonterey Capital Acquisition Corporation
$ 3.54
(-49.50%)
364.7k
MCACUMonterey Capital Acquisition Corporation
$ 7.64
(-28.40%)
2.61k
GENEGenetic Technologies Ltd
$ 0.80
(-27.93%)
780.46k
KZIAKazia Therapeutics Ltd
$ 0.8975
(-27.62%)
25.62M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.237
(-1.54%)
286.13M
NVDANVIDIA Corporation
$ 129.24
(1.44%)
251.69M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
(21.92%)
192.82M
LCIDLucid Group Inc
$ 4.25
(25.00%)
167.79M

MEDP Discussion

View Posts
MiamiGent MiamiGent 1 year ago
Hi OJ, unfortunately I'm out of that issuse. I'm struggling with MCRB right now.
GL
MG
👍️ 1
OncoJock OncoJock 1 year ago
nice post

more, please

What do you make of this recent sale of roughly 30,000 shares of stock reported to the SEC by Stephen Ewald at Medpace Investors LLC?

Apparently the sale was timed to coincide with release of a good 1Q 2023 earnings report? They sold at around $221 per share, and the price has fallen to under $200 just a few days later.

Best wishes,

-- OJ
👍️0
OncoJock OncoJock 1 year ago
This forum needs some fresh posts.

I like this stock. I discovered it when I was researching publicly held contract research organizations. (This is related to my line of work as a medical writer specializing in oncology drug development.) Other CROs I discovered about the same time included Charles River Laboratories, Parexel, PPD, PRA Health Sciences, Syneos, Covance, and ICON. About the same time I also began to invest in laboratory supply houses including BioRad, Thermo-Fisher, Perkin-Elmer, and Danaher.

I first bought shares of MEDP in 2017, paying about $28 each. I've bought and sold a lot of shares since then. My current cost basis is $154 per share. At current prices, my stake in MEDP accounts for about 19% of my brokerage account, so I pay pretty close attention to ups and downs of the share price.

If anyone wishes to discuss the latest earnings report (which beat predictions on both earnings and revenue) I'd welcome the opportunity.

Cheers!

-- OJ
👍️0
MiamiGent MiamiGent 2 years ago
MEDP MEDPACE HOLDINGS INC
$214.51 +55.87 (+35.22%)
As of Oct-25-202210:10:18 AM ET

https://stockcharts.com/h-sc/ui?s=MEDP

Contract Research Organization Medpace Lifts FY22 Guidance, Highlights FY23 Outlook
By Benzinga — 7:29 AM ET 10/25/22
Medpace Holdings Inc's (NASDAQ:MEDP) Q3 revenue increased 29.8% Y/Y to $383.7 million, beating the consensus of $357.18 million, representing a backlog conversion rate of 17.7%.
On a constant currency organic basis, Q3 revenue was up 31.9%.
As of September 30, 2022, Backlog grew 20.9% to $2.2 billion. Net new business awards were $470.9 million, representing a net book-to-bill ratio of 1.23x.
Q3 EBITDA increased 48.5% to $89.3 million, or 23.3% of revenue, compared to $60.1 million, or 20.3% of revenue, a year ago.
Medpace posted an EPS of $2.05, up from $1.29 a year ago and beating the consensus of $1.47.
Financial Guidance: Medpace raised FY22 sales guidance to $1.44-$1.46 billion, versus the prior guidance of $1.405-$1.435 billion and the consensus of $1.41 billion.
EBITDA is expected to be $302-$310 million, versus the previous guidance of $268-$280 million
Medpace expects EPS of $6.88-$7.00 compared to prior guidance of $6.07-$6.36 and the consensus of $6.15.
For FY23, the company forecasts sales of $1.68-$1.74 billion, with EBITDA of $325-$350 million.
Price Action: MEDP shares traded higher by 28.13% at $203.26 in premarket on the last check Tuesday.

Company Profile
Sector Health Care
Industry Life Sciences Tools & Services
Company Location Cincinnati, OH

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
👍️ 1

Your Recent History

Delayed Upgrade Clock